Christophe Nicot, Kansas University Medical Center, USA
Call for Papers: Molecular understanding and clinical aspects of immunotherapy in the treatment of cancer
Molecular Cancer invites submissions to this article collection. Topics of interest include, but are not limited to, adoptive cellular immunotherapy, chimeric antigen receptor T-cell (CAR-T) immunotherapy, immune checkpoint inhibitors, modulators of tumor microenvironment, and drug resistance mechanisms in immunotherapy. The collection is open to submissions from August 15th to November 15th 2022.
2022 Special Issues
- Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments
- Genome Editing and the Future of Personalized and Targeted Cancer Medicine
urzine / Getty Images / iStock
Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments
This special issue published by Molecular Cancer focuses on the clinical aspects of liquid biopsies, in particular validation of novel biomarkers that may serve as signature for non-invasive early detection of cancerous cells, predict patients' risks of disease progression and response to specific therapies.
vchalup / stock.adobe.com
Genome Editing and the Future of Personalized and Targeted Cancer Medicine
Molecular Cancer is excited to present a series of original research and review articles related to genome editing and reprogramming.
Editor-in-Chief
Aims and scope
Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.
Articles
-
-
The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy
-
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
-
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
-
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates
-
Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling
-
mRNA vaccine for cancer immunotherapy
-
The complexity of NF-κB signaling in inflammation and cancer
-
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition
-
Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer
2021 Thematic Series: mRNA therapies and mRNA vaccines in cancer
Molecular Cancer is delighted to announce its new thematic series: mRNA therapies and mRNA vaccines in cancer
Click here to access all thematic series published to date in Molecular Cancer.
Featured Article: Role of the NLRP3 inflammasome in cancer
In this review, Sahebkar et al. summarize the current knowledge on the contribution of the NLRP3 inflammasome on potential cancer promotion and therapy.
CAHON: Stop hate crimes and racism
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. Molecular Cancer is proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Recognising Editorial Excellence
Molecular Cancer is a top rated Springer Nature journal. Prof. Christophe Nicot and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.
What is trending?
Click here to see which articles published in Molecular Cancer have been shared the most in 2021.
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
Annual Journal Metrics
-
Citation Impact
41.444 - 2-year Impact Factor (2021)
30.612 - 5-year Impact Factor (2021)
5.195 - Source Normalized Impact per Paper (SNIP)
6.896 - SCImago Journal Rank (SJR)Speed
7 days to first decision for all manuscripts (Median)
43 days to first decision for reviewed manuscripts only (Median)Usage
2,680,902 Downloads (2021)
1067 Altmetric mentions (2021)